Abstract
Rationale & objective: Acute kidney injury (AKI) is common in patients with coronavirus disease 2019 (COVID-19) and associated with poor outcomes. Urinary biomarkers have been associated with adverse kidney outcomes in other settings and may provide additional prognostic information in patients with COVID-19. We investigated the association between urinary biomarkers and adverse kidney outcomes among patients hospitalized with COVID-19.
Study design: Prospective cohort study.
Setting & participants: Patients hospitalized with COVID-19 (n=153) at 2 academic medical centers between April and June 2020.
Exposure: 19 urinary biomarkers of injury, inflammation, and repair.
Outcome: Composite of KDIGO (Kidney Disease: Improving Global Outcomes) stage 3 AKI, requirement for dialysis, or death within 60 days of hospital admission. We also compared various kidney biomarker levels in the setting of COVID-19 versus other common AKI settings.
Analytical approach: Time-varying Cox proportional hazards regression to associate biomarker level with composite outcome.
Results: Out of 153 patients, 24 (15.7%) experienced the primary outcome. Twofold higher levels of neutrophil gelatinase-associated lipocalin (NGAL) (HR, 1.34 [95% CI, 1.14-1.57]), monocyte chemoattractant protein (MCP-1) (HR, 1.42 [95% CI, 1.09-1.84]), and kidney injury molecule 1 (KIM-1) (HR, 2.03 [95% CI, 1.38-2.99]) were associated with highest risk of sustaining primary composite outcome. Higher epidermal growth factor (EGF) levels were associated with a lower risk of the primary outcome (HR, 0.61 [95% CI, 0.47-0.79]). Individual biomarkers provided moderate discrimination and biomarker combinations improved discrimination for the primary outcome. The degree of kidney injury by biomarker level in COVID-19 was comparable to other settings of clinical AKI. There was evidence of subclinical AKI in COVID-19 patients based on elevated injury biomarker level in patients without clinical AKI defined by serum creatinine.
Limitations: Small sample size with low number of composite outcome events.
Conclusions: Urinary biomarkers are associated with adverse kidney outcomes in patients hospitalized with COVID-19 and may provide valuable information to monitor kidney disease progression and recovery.
Keywords: Acute kidney injury (AKI); COVID-19 prognosis; chronic kidney disease (CKD); coronavirus disease 2019 (COVID-19); death; dialysis; epidermal growth factor (EGF); inflammatory marker; kidney injury molecule 1 (KIM-1); monocyte chemoattractant protein 1 (MCP-1); neutrophil gelatinase-associated lipocalin (NGAL); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); subclinical AKI; tubular injury; urinalysis; urinary biomarkers; urine microscopy.
【저자키워드】 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), dialysis, Coronavirus disease 2019 (COVID-19), Urinalysis, death, Inflammatory marker, Acute kidney injury (AKI), COVID-19 prognosis, chronic kidney disease (CKD), epidermal growth factor (EGF), kidney injury molecule 1 (KIM-1), monocyte chemoattractant protein 1 (MCP-1), neutrophil gelatinase-associated lipocalin (NGAL), subclinical AKI, tubular injury, urinary biomarkers, urine microscopy., 【초록키워드】 COVID-19, coronavirus disease, Inflammation, Coronavirus disease 2019, coronavirus, Biomarker, Hospitalized, neutrophil, risk, Acute kidney injury, Chronic kidney disease, progression, outcome, prospective cohort study, severe acute respiratory syndrome Coronavirus, dialysis, cohort study, monocyte, Kidney injury, kidney, outcomes, Protein, AKI, Urinalysis, Microscopy, Prospective, Patient, Kidney disease, Urine, MCP-1, Hospital admission, discrimination, prognostic, respiratory, information, moderate, patients, association, COVID-19 prognosis, Evidence, Combination, creatinine, Inflammatory, repair, Injury, Composite, COVID-19 patient, evidence of, epidermal growth factor, serum creatinine, acute respiratory syndrome, Sample size, Primary outcome, acute respiratory syndrome coronavirus, acute respiratory syndrome coronavirus 2, individual, rationale, lower risk, small sample size, growth factor, monocyte chemoattractant protein 1, MONITOR, KDIGO, urinary, setting, EGF, defined, highest, investigated, elevated, events, provided, comparable, epidermal, Cox proportional hazard, Improving, patients hospitalized, patients with COVID-19, with COVID-19, 【제목키워드】 COVID-19, urinary, Significance,